You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

14 Items
Other Name(s): Tafinlar® (Novartis)
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
  • daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma and other indications, according to specific clinical criteria
Aug 2017
Other Name(s): DTIC® (generic brand available)
Aug 2016
Other Name(s): Cosmegen® (Recordati)
May 2016
Other Name(s): Darzalex® (Janssen Inc.)
Sep 2017
Other Name(s): Aranesp ® (Amgen)
Funding:
Exceptional Access Program
  • darbepoetin - Anemia secondary to MDS, with specific criteria
ODB Limited Use
  • darbepoetin - Patients with cancer diagnosis and receiving chemotherapy, with specific criteria
Jun 2017
Other Name(s): Sprycel® (Bristol-Myers Squibb)
Funding:
Exceptional Access Program
  • daSAtinib - PH+ ALL, with specific criteria
  • daSAtinib - Ph+ CML in the chronic phase, with specific criteria
  • daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Oct 2016
Other Name(s): Cerubidine® (multiple brands available)
Aug 2016
Other Name(s): Firmagon® (Ferring)
Funding:
ODB - General Benefit
  • degarelix
Mar 2013
Other Name(s): Xgeva® (Amgen)
Funding:
Exceptional Access Program
  • denosumab - Bony metastases in hormone refractory prostate cancer, with specific criteria
New Drug Funding Program
  • Denosumab - Hormone Refractory Prostate Cancer
Aug 2017
Jan 2018
Other Name(s): Zinecard® (Pfizer)
Apr 2016
Other Name(s): Taxotere® (multiple brands available)
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Trastuzumab with First Line Docetaxel - Metastatic Breast Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Nov 2017